National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients
Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months. International recommendations have diffused this option.It is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of LMWH.
Neoplasms|Venous Thromboembolism
PROCEDURE: VTE treatment in cancer patient description
Evaluation of the adherence to recommendations of VTE treatment in cancer patients, Proportion of patients treated for evolutive VTE according to international recommandations Patients could be hospitalised or could be out patient, At baseline (J0)
Evaluation of VTE disease according to cancer diagnosis (proportion of SVT (Superficial Venous Thrombosis), DVT (Deep Venous Thrombosis), PE (Pulmonary Embolism), Percentage of VTE (PE,DVT,SVT)and cancer type, At baseline (J0)|Proportion of asymptomatic VTE disease for this population, percentage of VTE and cancer status (local, metastatic), At baseline (J0)|Feasibility of self injections for VTE treatment in cancer patients., percentage of patients practising self injections, At baseline (J0)|Proportion of patients with catheter thrombosis, Percentage of patients receiving novel cancer therapies, At baseline (J0)
Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months. International recommendations have diffused this option.It is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of LMWH.